Literature DB >> 34097142

Multidisciplinary Management of Adolescent and Young Adult Patients with Hodgkin Lymphoma.

Emily Galloway1, Melody Griffith2, Allison Rosenthal3,4.   

Abstract

OPINION STATEMENT: Successful management of adolescent and young adult patients with Hodgkin lymphoma (HL) requires a multidisciplinary approach to care with special attention paid to the unique medical, logistical, and psychosocial challenges faced by this group. The emotional and social changes and big life transitions that occur between the ages of 15 and 39 result in a broad scope of supportive care needs that differ from children or adults in similar circumstances. Currently, care of adolescent and young adult (AYA) patients with HL may be fractured across the pediatric-adult cancer care continuum resulting in this group being less well studied than pediatric or adult patients in general. In order to optimize outcomes, these patients need access to medical oncologists and radiation oncologists, advanced practice providers (APPs), psychologists/social work, financial support services, fertility specialists, survivorship care, and advocates with AYA expertise that can help navigate the healthcare system. A strong AYA support system established early with targeted education and resources may influence treatment compliance and likelihood of long-term follow-up. Surveys of the AYA cancer population have identified areas of opportunity for the healthcare team to collaborate to identify needs, design interventions to meet them, and ultimately develop evidence-based guidelines that will enable us to offer AYAs with HL the quality care they deserve.

Entities:  

Keywords:  Adolescent; Hodgkin; Multidisciplinary; Psychosocial; Young adult

Mesh:

Year:  2021        PMID: 34097142     DOI: 10.1007/s11864-021-00861-0

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  48 in total

1.  Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults.

Authors:  Erlyn C Smith; Argyrios Ziogas; Hoda Anton-Culver
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

2.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Authors:  Andreas Engert; Annette Plütschow; Hans Theodor Eich; Andreas Lohri; Bernd Dörken; Peter Borchmann; Bernhard Berger; Richard Greil; Kay C Willborn; Martin Wilhelm; Jürgen Debus; Michael J Eble; Martin Sökler; Antony Ho; Andreas Rank; Arnold Ganser; Lorenz Trümper; Carsten Bokemeyer; Hartmut Kirchner; Jörg Schubert; Zdenek Král; Michael Fuchs; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Volker Diehl
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

3.  Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group.

Authors:  Suzanne L Wolden; Lu Chen; Kara M Kelly; Philip Herzog; Gerald S Gilchrist; John Thomson; Richard Sposto; Marshall E Kadin; Raymond J Hutchinson; James Nachman
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

4.  Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031.

Authors:  Debra L Friedman; Lu Chen; Suzanne Wolden; Allen Buxton; Kathleen McCarten; Thomas J FitzGerald; Sandra Kessel; Pedro A De Alarcon; Allen R Chen; Nathan Kobrinsky; Peter Ehrlich; Robert E Hutchison; Louis S Constine; Cindy L Schwartz
Journal:  J Clin Oncol       Date:  2014-10-13       Impact factor: 44.544

5.  Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

Authors:  Marc P E André; Théodore Girinsky; Massimo Federico; Oumédaly Reman; Catherine Fortpied; Manuel Gotti; Olivier Casasnovas; Pauline Brice; Richard van der Maazen; Alessandro Re; Véronique Edeline; Christophe Fermé; Gustaaf van Imhoff; Francesco Merli; Réda Bouabdallah; Catherine Sebban; Lena Specht; Aspasia Stamatoullas; Richard Delarue; Valeria Fiaccadori; Monica Bellei; Tiana Raveloarivahy; Annibale Versari; Martin Hutchings; Michel Meignan; John Raemaekers
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

6.  Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.

Authors:  Michael Fuchs; Helen Goergen; Carsten Kobe; Georg Kuhnert; Andreas Lohri; Richard Greil; Stephanie Sasse; Max S Topp; Erhardt Schäfer; Bernd Hertenstein; Martin Soekler; Martin Vogelhuber; Josée M Zijlstra; Ulrich Bernd Keller; Stefan W Krause; Martin Wilhelm; Georg Maschmeyer; Julia Thiemer; Ulrich Dührsen; Julia Meissner; Andreas Viardot; Hans Eich; Christian Baues; Volker Diehl; Andreas Rosenwald; Bastian von Tresckow; Markus Dietlein; Peter Borchmann; Andreas Engert
Journal:  J Clin Oncol       Date:  2019-09-10       Impact factor: 44.544

7.  A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

Authors:  Cindy L Schwartz; Louis S Constine; Doojduen Villaluna; Wendy B London; Robert E Hutchison; Richard Sposto; Steven E Lipshultz; Charles S Turner; Pedro A deAlarcon; Allen Chauvenet
Journal:  Blood       Date:  2009-07-07       Impact factor: 22.113

8.  Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.

Authors:  J Wolfson; C-L Sun; L Wyatt; W Stock; S Bhatia
Journal:  Leukemia       Date:  2017-02-20       Impact factor: 11.528

9.  Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Authors:  Peter Johnson; Massimo Federico; Amy Kirkwood; Alexander Fosså; Leanne Berkahn; Angelo Carella; Francesco d'Amore; Gunilla Enblad; Antonella Franceschetto; Michael Fulham; Stefano Luminari; Michael O'Doherty; Pip Patrick; Thomas Roberts; Gamal Sidra; Lindsey Stevens; Paul Smith; Judith Trotman; Zaid Viney; John Radford; Sally Barrington
Journal:  N Engl J Med       Date:  2016-06-23       Impact factor: 91.245

10.  Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study.

Authors:  Theresa H M Keegan; Mindy C DeRouen; Helen M Parsons; Christina A Clarke; Debbie Goldberg; Christopher R Flowers; Sally L Glaser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-01-29       Impact factor: 4.090

View more
  1 in total

Review 1.  Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy.

Authors:  Roser Velasco; Eva Domingo-Domenech; Anna Sureda
Journal:  Cancers (Basel)       Date:  2021-12-05       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.